<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163233">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02042196</url>
  </required_header>
  <id_info>
    <org_study_id>06-0537 SHAPE2</org_study_id>
    <nct_id>NCT02042196</nct_id>
  </id_info>
  <brief_title>Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women</brief_title>
  <acronym>SHAPE2</acronym>
  <official_title>Biological Mechanisms of Vascular Dysfunction With Age and Estrogen Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      As women get older and go through menopause, levels of the female reproductive hormone
      estradiol decrease to low levels. Also with aging, the functioning of the arteries declines.
      Over time this vascular dysfunction can lead to health problems such as high blood pressure
      and heart disease. This study is being done to help determine what causes arteries to become
      unhealthy in postmenopausal women, who have low levels of the female reproductive hormone
      estradiol. In this study we will test whether low levels of tetrahydrobiopterin (BH4), a
      natural substance in the body that can cause the arteries to expand, explains why arteries
      become unhealthy in women with low levels of estradiol. To answer this question, we will
      study how vascular function changes with a medication that causes a short-term increase in
      BH4 levels when estradiol is lowered with a medication, compared to when estradiol is
      normal. We will also determine whether the administration of the antioxidant vitamin C,
      along with the medication to increase BH4 levels, will normalize vascular health in
      perimenopausal and postmenopausal women, and in women who have their estradiol levels
      lowered.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change in brachial artery flow-mediated dilation</measure>
    <time_frame>4-5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in carotid artery compliance and endothelial cell protein expression</measure>
    <time_frame>4-5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Menopause</condition>
  <condition>Aging</condition>
  <condition>Vascular Health</condition>
  <arm_group>
    <arm_group_label>Pre or Early perimenopausal 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline experiment: Subjects randomized to either 1) KUVAN (10mg/kg body weight) crossover to placebo OR 2) placebo crossover to KUVAN
Hormone modification: GnRH antagonist with Cetrotide (0.25mg/d) + placebo transdermal patch, then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre or Early Perimenopausal 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline experiment: Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN
Hormone modification: Estrogen add-back with Cetrotide + Climara (0.075mg/d), then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Perimenopausal and Postmenopausal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN
No hormone modification.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KUVAN</intervention_name>
    <description>KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.</description>
    <arm_group_label>Pre or Early perimenopausal 1</arm_group_label>
    <arm_group_label>Pre or Early Perimenopausal 2</arm_group_label>
    <arm_group_label>Late Perimenopausal and Postmenopausal</arm_group_label>
    <other_name>Tetrahydrobiopterin or BH4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills designed to match the dissolvable KUVAN pills</description>
    <arm_group_label>Pre or Early perimenopausal 1</arm_group_label>
    <arm_group_label>Pre or Early Perimenopausal 2</arm_group_label>
    <arm_group_label>Late Perimenopausal and Postmenopausal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrotide</intervention_name>
    <description>Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.</description>
    <arm_group_label>Pre or Early perimenopausal 1</arm_group_label>
    <arm_group_label>Pre or Early Perimenopausal 2</arm_group_label>
    <other_name>Cetrorelix acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Climara</intervention_name>
    <description>0.075mg/d transdermal patch will be placed on skin.</description>
    <arm_group_label>Pre or Early Perimenopausal 2</arm_group_label>
    <other_name>Estradiol transdermal patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo transdermal patch</intervention_name>
    <arm_group_label>Pre or Early perimenopausal 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age criteria established for pre-, peri- and postmenopausal women, and if
             postmenopausal at least 1 year beyond menopause

          -  resting blood pressure &lt;140/90 mmHg 81; 2) plasma glucose concentrations &lt;110 mg/dl
             under fasting conditions

          -  sedentary or recreationally active (&lt;3 days of vigorous aerobic exercise)

          -  no use of OCs, HT, or other medications that might influence cardiovascular function

          -  nonsmokers

          -  no use of vitamin supplements, NSAIDS or willing to stop use for duration of the
             study

          -  not taking any other medications that would interact with cetrotide, E2 patch, or
             KuvanÂ® to confound interpretation of results

        Exclusion Criteria:

          -  history of or active estrogen-dependent neoplasms, acute liver or gallbladder
             disease, vaginal bleeding, venous thromboembolism, hypertriglyceridemia, and CVD

          -  known allergy to transdermal patch, GnRHant (i.e., hypersensitivity to cetrorelix,
             extrinsic peptide hormones, mannitol, GnRH, benzyl alcohol - the vehicle for
             injection of cetrorelix), or KUVAN

          -  history of stomach ulcer or bleeding

          -  other contraindications to HRT, GnRHant, and KUVAN (i.e., taking Levodopa,
             medications that can inhibit folate metabolism including methotrexate)

          -  pregnant or currently breastfeeding

          -  Other conditions for which individuals will be excluded from the study include:
             diabetes, active infection, history of seizures or disease that affects the nervous
             system, sepsis or an abnormal resting ECG
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerrie Moreau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amber Palumbo</last_name>
    <phone>720-848-6475</phone>
    <email>Amber.Palumbo@ucdenver.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerrie Moreau, PhD</last_name>
      <phone>303-724-1914</phone>
      <email>kerrie.moreau@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Kerrie Moreau, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 17, 2014</lastchanged_date>
  <firstreceived_date>January 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado, Denver</investigator_affiliation>
    <investigator_full_name>Kerrie Moreau</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>women</keyword>
  <keyword>estrogen deficiency</keyword>
  <keyword>sex hormones</keyword>
  <keyword>adiposity</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>antioxidants</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
